Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The governance of the European patent system (PATGOV)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Norway
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-06-01
End date: 2020-05-31
Duration (months): 24.0
Total project cost (EUR): 208400.4
EU funding (EUR): 208400.4
Participants: 1
Project status: CLOSED

The functioning of the European patent system has been called into question from many different angles. The criticisms range from discontent with low patent quality and with backlogs in patent examination to ethical concerns about ‘patents-on-life’, and from accountability/legitimacy problems of the European Patent Office (EPO) to fundamental doubt about whether patenting fits the current research and innovation models, especially in emerging technologies such as for example biotechnology. The current European patent system is however a rather closed system (that primarily services patent applicants) and it is not inclined to take on board such criticisms and/or considerations that are relevant to society at large. Put differently: the system is currently not aligned with the main principles of Responsible Research and Innovation (RRI). Research in this field seems however to be stuck in –very similar- diagnoses of what is wrong with the system. The project takes the analysis an important step further by looking at changes needed in the governance of the European patent system in order to substantially enhance its responsiveness to societal stakeholders. It tries to explain the limited actual use of inclusive mechanisms that are currently available in the European patent system. It assesses similar mechanisms that are used by other regional patent systems and could potentially be transferred to the European patent system. It looks at changes needed in the institutional set-up of the European patent system in order to enhance responsiveness. The project also analyses changes needed in European patent law that could open up the patent system to more inclusive IP rights, and it addresses the likely impact the new EU Unitary Patent will have on the responsiveness of the European patent system.

Keywords: european patent system,public sector reform,governance
LAM561 BEATS PANCREATIC CANCER (PANC561)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Society and Enterprise panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-04-01
End date: 2023-03-31
Duration (months): 24.0
Total project cost (EUR): 160932.48
EU funding (EUR): 160932.48
Participants: 1
Project status: CLOSED

Pancreatic cancer is a highly aggressive type of cancer, with poor prognosis and few effective therapeutic options. At the time of diagnosis only 20% of patients are eligible for surgery, the development of metastasis has already occurred. The life expectancy of these patients is 6-11 months (stage3) or 2-6 months (stage IV). Laminar Pharmaceuticals SL is pioneer in the development of bioactive molecules that act through modulation of the lipid composition of the cell membrane regulating key signaling pathways for different pathologies, including cancer. Recently, Laminar Pharma has demonstrated the high safety and promising efficacy of its most advanced drug in clinical development, LAM561 which is being developed for the treatment of glioblastoma. The clinical study phase IIb/III of LAMP561 in glioblastoma, which evaluates the pharmacological safety of LP561 in combination with the standard treatment for this disease, is currently being completed, without observed severe adverse effects attributable to LAM561. The current project aims to carry out a preclinical study to evaluate the efficacy and safety of the anti-tumor drug LAM561 in cell and animal models of pancreatic cancer as monotherapy or in combination with standard chemotherapeutics. In addition, the study of cell migration in cell and animal models of pancreatic cancer may allow to explore the antimetastatic effect of LP561 pancreatic cancer, opening a new line of development in the company. This project aims to expand the product indications by including data on its safety and efficacy in the treatment of pancreatic cancer which requires urgent solutions. Therefore, the completion of the preclinical study would allow, at the end of the proposed studies, to launch human clinical trials to give pancreatic cancer patients the option of benefiting from this therapy more quickly. Furthermore, this represents a great opportunity which may foster the carrier of the current applicant researcher.

Keywords: pancreatic cancer,membrane lipid therapy,sphingomyelin synthase,antimigratory activity
Linking sequence to function of long noncoding RNAs with CRISPR. (CRISPR-Locate)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland,Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-08-01
End date: 2023-07-31
Duration (months): 24.0
Total project cost (EUR): 184590.72
EU funding (EUR): 184590.72
Participants: 2
Project status: SIGNED

A great surprise in the wake of the Human Genome Project has been the discovery of vast numbers of RNAs that do not encode proteins. Alongside 19,000 protein-coding genes, our genome contains at least 20,000 long noncoding RNA (lncRNA) genes, but recent estimates push that number to 100,000. Extensive annotation efforts are presently discovering lncRNAs far faster than their functions can be elucidated, and thus only <1% of lncRNAs have been experimentally characterised. These discoveries have created a grand challenge of understanding lncRNAs’ biological significance. To do this, we must solve the pressing question of how lncRNAs’ functions are encoded in their primary sequence. As a proxy of lncRNAs function we can use subcellular localisation since lncRNAs function as a mature RNA molecule. One hypothesis is that, similar to proteins, lncRNAs are modular molecules composed of separable functional domains. Previous studies, including my own, have used conventional methods to identify domains in a handful of lncRNAs by laborious deletion experiments. I propose to advance this field, via a novel high-throughput technique, CRISPR-Locate, capable of detecting lncRNA domains and their function in their natural endogenous context. I will delete ⁓1000 different lncRNA domains at the same time and simultaneously insert RNA tags at their place. Subsequently, I will fractionate cells by their compartments and purify tagged lncRNAs. Afterwards, I will sequence all the tagged lncRNAs and, by comparing the change in the subcellular localisation between mutated and wild type cells, I will identify which domains are responsible for subcellular localization. Finally, I will use CRISPR-Locate to create a map of lncRNA domains, an invaluable resource linking sequence to function, and bring us a step closer to unlocking the potential of 10^4 novel genes in medicine and biology.

Keywords: long non coding rna lncrna,crispr cas9,subcellular localisation
Professional tool to facilitate data collection and digitalization in field trials for plant breeding and seed commercialisation (BreedIT-FIELD)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Israel
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-06-01
End date: 2016-08-31
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

We are a highly innovative company founded in 2013 for the development and marketing of a computerized and internet operated advanced decision support system for breeding. Based on our knowledge of the needs of the plant breeding sector we have designed BreedIT-Field a software tool for collecting plant phenotypes in the field which makes use of the latest ICT technology (computer vision, QR code scanning) to facilitate data collection, digitalization and analysis from breeding field trials and seed production fields. The main advantages of Breedit-Field are the following: -It will reduce time to market, by optimizing planning, management and execution of growing trials -It will reduce the overall costs of field trials up to 35% of breeding programs, by accelerating field inspections, eliminating costly errors, by optimising operators´ work and by reducing the administrative workload by the automatic generation of daily field books -It will facilitate communication and collaboration between research groups, field evaluation teams and production units across multiple locations worldwide optimizing breeding and seed production process. The development of Breedit-Field is of vital strategic importance for our company because it will open new business opportunities in line with our current know how and will boost our growth giving us a consolidated position at international level.

Keywords: breeding,field trial,seed production,agriculture,software
Aerospace propeller useful for diesel engines with extreme excitation of vibrations (ARGOS)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Czechia,Czechia,Czechia
Call: Powerplant Shaft Dynamic and associated damping system (H2020-CS2-CFP02-2015-01, 2015)
Start date: 2016-06-01
End date: 2019-09-30
Duration (months): 40.0
Total project cost (EUR): 524153.75
EU funding (EUR): 420495.0
Participants: 3
Project status: CLOSED

The project proposal is aimed at light weight and efficient jet-fuel aerospace propulsion units based on reciprocating engines. Aerospace propellers useful for jet-fuel reciprocating direct drive engines suffer by extreme excitation of vibrations. The objective of the project proposal is to design and test a new propeller useful for such operational conditions. The objective will be achieved by the following steps: 1. Definition of propeller design specifications with respect to the increased level of vibration excitation due to the specific characteristic of the direct drive jet-fuel reciprocating engines. 2. Design of the propeller and its parts and equipment with respect to the increased level of vibrations. 3. Production of the propeller system. 4. Engine testing of the propeller to demonstrate the achievements. During the first step an already existing propeller will be used for strain-gage measurements on an equivalent AVGAS engine and then of the target jet-fuel engine. Based on the measured differences of stress distribution and its cyclic components the new technical specifications will be established. Based on them a suitable propeller system will be designed, produced and tested. WOODCOMP staff has 25 years long experience in the development and serial production of propellers for reciprocating engines. WOODCOMP is approved by EASA and national CAA for design, production, testing and maintenance activities. JIHOSTROJ is a company experienced and approved for design and production of propeller governors. VZLU is a research and testing establishment with more than 90 years experience and tradition in aerospace activities.

Keywords: propeller,vibrations,jet fuel engine,reciprocating engine,diesel
Research Training Network on Integrated Component Cycling in Epithelial Cell Motility (InCeM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Germany,Israel,Austria,Austria,Germany,Germany,Germany,Switzerland,Sweden,Sweden,Netherlands,Netherlands,United Kingdom,Canada,United Kingdom,United Kingdom
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2014, 2014)
Start date: 2015-01-01
End date: 2018-12-31
Duration (months): 48.0
Total project cost (EUR): 3866665.32
EU funding (EUR): 3866665.32
Participants: 29
Project status: CLOSED

Cell migration (cell motility) is a fundamental biological process that is pivotal in (i) tissue formation and repair (health) and (ii) tissue invasion during carcinogenesis (disease). Understanding and controlling cell migration will have major clinical impact. Clarifying mechanisms driving cell motility has been challenging due to the complex underlying cellular mechanisms; these involve multiple components coordinated by structural, chemical and physical signals in terms of time and space. To accomplish breakthroughs in this field, researchers are needed who (i) master cutting-edge experimental techniques for monitoring the different cellular processes at high resolution and (ii) have competencies in theoretical science for integrating the resulting data sets into mechanistic mathematical models for predicting motile cell behaviour. The Research Training Network on Integrated Component Cycling in Epithelial Cell Motility (InCeM) aims to endow up-and-coming researchers with exactly these competencies. They will be able to develop and apply innovative devices for microscopic recording, image processing techniques, data analysis tools and modelling procedures for mechanistic understanding of cell migration. InCeM will focus on epithelial cells, since inducing motility in this cell type is clinically relevant for wound healing and cancer invasion. The ultimate goal is to control and manipulate cell migration for clinical applications. A dedicated multidisciplinary team of 11 beneficiaries from universities (4), research institutions (4) and industry (3), based in 5 European countries and Israel, together with 17 associated partners from the public and private sector, will train 15 Early Stage Researchers (ESRs) to use the relevant technologies and sciences and will offer business training to prepare them for successful careers in both academic and non-academic environments.

Keywords: cell migration,cytoskeleton,fluorescence microscopy,traction force microscopy,image analysis,mathematical modeling
Strengthening of scientific excellence of the National Veterinary Research Institute in animal health and food chain safety (VET-TWIN)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Germany,Poland,Denmark
Call: Twinning (H2020-TWINN-2015, 2015)
Start date: 2016-01-01
End date: 2018-12-31
Duration (months): 36.0
Total project cost (EUR): 970425.0
EU funding (EUR): 970425.0
Participants: 3
Project status: CLOSED

The general objective of the VET-TWIN project is to increase the potential and research capacity of the National Veterinary Research Institute (NVRI) by cooperation with internationally-leading counterparts from Germany (Federal Institute for Risk Assessment-BfR) and Denmark (Technical University of Denmark, National Veterinary Institute; DTU Vet) − to act in an international scientific and research environment as a leading institute in the fields of animal infectious diseases, zoonoses and food chain safety. The objective defined in such a way will be accomplished through a number of activities, in particular through the implementation of the Joint Strategy of Cooperation and Development, and by introduction of mechanisms for the interaction of scientists at the operational level, as well as through activities helping in the exchange of knowledge and experiences among scientists. The concept of the VET-TWIN project fully addresses the objectives of the Horizon 2020 programme. Through activities planned in order to increase the level of scientific excellence of the institute and its research staff, the project fully implements the specific objective Spreading Excellence and Widening Participation. The Implementation of the project fits directly in with the specific challenge of Twinning. By creating a partnership between the aforementioned entities, it will be possible to cooperate and exchange knowledge on an international level. Furthermore, the involvement of two scientific centres of excellent repute in the international research community to the VET-TWIN project, will prevent the crowding-out effect for an institution from a country with a lower Composite indicator of Research Excellence. The above-mentioned factors justify the need for the implementation of the project because it responds directly to the problems diagnosed within the Specific Challenge.

Keywords: animal health,food safety,trainings,research excellence,risk assessment
MicroRNA-based tool for non-invasive early-stage cancer diagnosis (GenomtecTumor)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Poland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-11-01
End date: 2020-04-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes. Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 million cases reported worldwide every year. Early cancer diagnosis is critical to its successful treatment, yet today’s technologies are limited in their accuracy, and are laborious and time consuming processes. Genomtec aims to address this challenge with its novel diagnostic system based on unique, patent pending amplification technology – Streamlined Nucleic Acid Amplification Technology (SNAATTM). Genomtec’s programme is built on many years of R&D activity and collaborative projects with academic and medical institutions in Poland. Using this robust molecular biology method for real-time amplification of nucleic acids, Genomtec’s cancer diagnostic test can be performed in 20 minutes at the point-of-care. Genomtec offers the possibility to accurately diagnose cancer early and reduce its financial burden on the economy by enabling more effective treatment and improved patient outcomes, including increased patient survival, increased post-treatment quality of life, and reduced patient distress during the diagnostic phase. Genomtec’s diagnostic device is unique and there are no competitors using the same molecular approach to diagnose cancer based on detection of tumour specific microRNA. The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for sales expansion. Genomtec plans to apply for the SME Phase 2 grant to take its product through device finalisation, clinical studies, and establishment of the distribution network. Genomtec has an established business development contact network and has been awarded numerous prizes for its innovativeness and potential for growth, e.g. The best non-US startup at Boston HUBWeek in October 2018.

Keywords: microrna,inaat,molecular diagnostics
Predictive Maintenance Tool for Non-Intrusive Inspection Systems (PMT4NIIS)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Action type: SME instrument
Countries involved: Bulgaria
Call: Engaging SMEs in security research and development (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-01-01
End date: 2018-06-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The importance of providing for effective, time and cost-saving maintenance of Non-Intrusive Inspection Systems (NIIS) cannot be overstated. For the purpose of our proposal, NIIS are X-ray systems deployed to inspect all types of parcels, baggage, cargo, vehicles, containers, and trains, in a non-intrusive manner. Over the past 10 years Danlex has realised sales of NIIS equipment and NIIS maintenance services totalling more than EUR 40 million in Bulgaria, Macedonia, and Kosovo. Airports, customs administrations, border police, harbours, and other authorities responsible for protecting the freedom and security of societies worldwide (security organisations) in the European Union and worldwide have been charged with: preventing global terrorist threats and illegal human trafficking; detecting and identifying illicit or undeclared goods; increasing security to the global supply chain. To tackle these challenges security organisations have increasingly been utilising NIIS equipment over the last two decades, as the most effective equipment for fulfilling their duties in compliance with the applicable regulations and standards. With the average NIIS lifespan of 10 years the maintenance has proved to be high and lead to much higher than anticipated running costs over the equipment’s lifetime, totalling to 100% of NIIS purchase price. To ensure value for money, it is important that NIIS operate with maximum efficiency and at the lowest possible level of maintenance and life-cycle costs. NIIS maintenance solution enabled by PMT (PMT4NIIS) will allow us to equip the security organisations and market stakeholders with the next generation of NIIS maintenance. Independent reports estimate that with reliability-centered maintenance powered by predictive models, stakeholders in other markets spend 15% of their overall maintenance time on Predictive Maintenance, yet achieve an impressive 50% decrease in maintenance costs.

Keywords: predictive,maintenance,inspection,detection,system,security,customs,airport,port,border,service,critical infrastructure,x ray